We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Fezolinetant

News List

Inventory of New Drug Targets in 2023 roger
May 21, 2024
In 2023, 49 new drugs received their first approval in the United States, the European Union, and Japan.
Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
August 08, 2019
Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY™ clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity.
Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
August 08, 2019
Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY™ clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity.